• Molecular NamePramipexole
  • SynonymFurfuryl Acetate; Pramipexol; Pramipexol [Spanish]; pramipexole; Pramipexole 2HCl Monohydrate; Pramipexole hydrochloride; Pramipexolum [Latin]
  • Weight211.333
  • Drugbank_IDDB00413
  • ACS_NO104632-26-0
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)1.48
  • pka8.5
  • LogD (pH=7, predicted)-1.15
  • Solubility (experiment)Insoluble
  • LogS (predicted, ACD/Labs)(ph=7)0.42
  • LogSw (predicted, AB/LogsW2.0)5.98
  • Sw (mg/ml) (predicted, ACD/Labs)2.76
  • No.of HBond Donors3
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds3
  • TPSA79.18
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA medication indicated for treating Parkinson's disease and restless legs syndrome (RLS). It is also sometimes used off-label as a treatment for cluster headache and to counteract the problems with sexual dysfunction experienced by some users of the selective serotonin reuptake inhibitor (SSRI) antidepressants.
  • Absorption_value95.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability93.0
  • Protein binding15.0
  • Volume of distribution (VD)7.3 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMinimal
  • Half life11.6 h
  • ExcretionRenal (90%) and fecal (2%)
  • Urinary Excretion90
  • Clerance8.2 ml/min/kg
  • ToxicityAdverse Events reported in patients treated with Mirapex with frequency more than 5% and numerically more frequent than placebo include: asthenia, general edema, nausea, constipation, peripheral edema, dizziness, somnolence, insomnia, hallucinations.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A